Clin2
NCT06731374Likely a fitRecruiting

New pneumonia vaccine study for healthy adults 18–50

Pneumococcal DiseasePneumococcal Carriage

Part of Infections clinical trials.

This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
106 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • You are between 18 and 50 years old.
  • You are in good health with no serious chronic conditions (like diabetes, heart disease, or asthma requiring daily medication).
  • You have not had a pneumococcal vaccine (like Prevnar or Pneumovax) in the past 5 years and will not get one during the study.
  • You are not currently smoking or vaping, and have not done so in the last 6 months.
  • You are not taking long-term antibiotics or medications that affect your immune system.
  • You agree to attend all study visits and keep an online diary.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06044077Recruiting· Phase 3
Testing a new pneumonia vaccine in healthy people

This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.

Chengdu, Sichuan
NCT07135453Recruiting· Phase 4
Pneumonia vaccine study for healthy adults

This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.

Birmingham, Alabama
NCT07660198Recruiting· Phase 3
Pneumonia vaccine catch-up study for kids and teens

This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.

Birmingham, Alabama
NCT07629440Recruiting· Phase 3
New Pneumococcal Vaccine Study for Infants

This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.

Birmingham, Alabama
NCT06608199Recruiting· Phase 3
Pneumonia vaccine study for healthy infants

This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.

Denpasar, Bali
NCT07754539Recruiting· Phase 3
Testing a new pneumonia vaccine in healthy Chinese infants

This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.

Hezhou, Guangxi

Hear when a new Pneumococcal Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.